Back to top
more

OrthoPediatrics (KIDS)

(Real Time Quote from BATS)

$24.70 USD

24.70
110,272

-1.23 (-4.74%)

Updated Oct 7, 2024 03:52 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (61 out of 252)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Bruker Stock Gains From Its Latest Acquisition of Dynamic Biosensors

by Zacks Equity Research

BRKR acquires Dynamic Biosensors or DBS. DBS's unique products, along with BRKR's SPR portfolio, should help the latter establish a leading biosensors business.

New Animal Health Products, Vaccine Sales Support PAHC Stock

by Zacks Equity Research

Phibro Animal Health is focusing on new developments, incremental registrations and volumes of existing vaccine technologies.

Down -15.65% in 4 Weeks, Here's Why You Should You Buy the Dip in OrthoPediatrics (KIDS)

by Zacks Equity Research

OrthoPediatrics (KIDS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

HYPR Achieves Positive Swoop System Data for ECMO: Stock to Rise?

by Zacks Equity Research

Hyperfine announces a publication on using the Swoop system for patients on ECMO support. The study showed the safety of using an ultra-low-field portable brain MRI on patients undergoing ECMO.

QIAGEN Launches QIAcuityDx Digital PCR System: Stock to Gain?

by Zacks Equity Research

QGEN expands its digital PCR portfolio with the newly launched QIAcuityDx Digital PCR System. The system will be used for clinical testing in oncology across North America and Europe.

BSX Stock Gains From FARAPULSE PFA's PMDA Approval in Japan

by Zacks Equity Research

Boston Scientific achieves PMDA approval for its FARAPULSE PFA System in Japan. The company expects to launch the system in the country in the upcoming weeks.

HOLX Stock Gains From New Offerings Despite Macro Issues

by Zacks Equity Research

In Breast Health, Hologic expands its product offering from imaging to cover the continuum of breast cancer care, including biopsy and surgery.

VRNOF Stock Likely to Gain From Its Newly Opened Dispensary in Phoenix

by Zacks Equity Research

Verano is set to open a new Zen Leaf Arcadia in Phoenix, AZ, today. Zen Leaf Arcadia is located at 2710 E Indian School Road, Phoenix. It will be open daily from 8 a.m. to 10 p.m. local time.

Favorable Data on Swoop Portable MRI Likely to Support Hyperfine Stock

by Zacks Equity Research

Compared to conventional MRI, which takes an average of 27.7 hours, the Swoop system of HYPR operates with a median time-to-scan of 2.5 hours.

QIAGEN Stock Likely to Gain From PreAnalytiX's Newly Launched PAXgene

by Zacks Equity Research

PreAnalytiX, a joint venture of QGEN and BD, introduces the PAXgene Urine Liquid Biopsy Set. QGEN will commercialize the latest set.

Inspira Stock to Gain From its Appearance at Annual ELSO Conference

by Zacks Equity Research

At the 34th annual ELSO conference in Detroit, IINN will present its FDA-cleared latest and future technology, the INSPIRA ART100 system.

Bears are Losing Control Over OrthoPediatrics (KIDS), Here's Why It's a 'Buy' Now

by Zacks Equity Research

OrthoPediatrics (KIDS) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Quest Diagnostics Stock Gains From New Offerings, Customer Wins

by Zacks Equity Research

A key driver in Brain Health growth is Quest Diagnostics' Alzheimer's disease portfolio, featuring the AD-Detect blood testing services and the CSF tests.

QGEN Stock Might Rise on Partnership With Bode for GEDmatch PRO

by Zacks Equity Research

QIAGEN announces exclusive global commercial partnership with Bode Technology. Per the agreement, Bode will manage all commercial transactions for QIAGEN's GEDmatch PRO globally.

STIM Stock Likely to Gain From Updated TMS Coverage

by Zacks Equity Research

Neuronetics announces that TMS coverage has been updated to reduce access barriers for patients with MDD. In line with this, BCBS and Louisiana Medicaid have expanded their TMS coverage.

TNDM Stock Likely to Gain From Innovation Amid Competition

by Zacks Equity Research

Tandem Diabetes is driving transformative innovation to help reduce the burden of diabetes and create new possibilities for people living with the condition.

EDAP's Avenda Deal for AI-Assisted Cancer Care Likely to Drive Stock

by Zacks Equity Research

When combined with EDAP's Focal One platform, Avenda's Unfold AI enables more accurate and patient-specific treatment options.

BiomX Stock Gains From Favorable Study Data Presentation on BX004

by Zacks Equity Research

PHGE is set to present data from its Phase 1b/2a study for BX004 at the North American Cystic Fibrosis Conference in Boston on Sept. 27 and Sept. 28.

VERO Stock Likely to Get Support From New Regulatory Nod in Australia

by Zacks Equity Research

The latest approval for Venus Concept in Australia reinforces its position as a global player in the aesthetic technology space.

Abbott Stock Hurt by Macroeconomic Issues & FX Headwind

by Zacks Equity Research

Foreign exchange fluctuation is a major headwind for ABT, as a considerable percentage of its revenues comes from outside the United States.

QGEN Stock Likely to Gain From Newly Launched Assays for QIAcuity

by Zacks Equity Research

QIAGEN launches 100 new assays for QIAcuity. The newly launched assays are now available through the company???s GeneGlobe platform.

BSX Gets FDA Nod on INGEVITY+ Pacing Lead in the LBBA: Stock to Gain?

by Zacks Equity Research

Boston Scientific received FDA approval on the expanded indication for INGEVITY+ Pacing Leads. Data demonstrated this lead to be safe and effective for LBBA pacing.

Does OrthoPediatrics (KIDS) Have the Potential to Rally 36.3% as Wall Street Analysts Expect?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 36.3% in OrthoPediatrics (KIDS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

KIDS Stock Gains From Its New Enabling Technologies Division Launch

by Zacks Equity Research

OrthoPediatrics recently launched its Enabling Technologies division, set to generate sustainable revenue growth and gain access to new markets and specialties beyond orthopedics.

Can HITI Stock Get a Boost From Bricks-and-Mortar Sales in Q3 Earnings?

by Zacks Equity Research

Given High Tide's progress in executing its strategic initiatives, we expect it to report robust Q3 bricks-and-mortar segment sales.